The Present and Future
JACC Review Topic of the Week
Cardiovascular Effects of ADHD Therapies: JACC Review Topic of the Week

https://doi.org/10.1016/j.jacc.2020.05.081Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Use of prescription sympathomimetic drugs for treating ADHD has markedly increased in the United States.

  • ADHD medications, potent stimulants of the sympathetic nervous system, are associated with adverse cardiovascular events.

  • ADHD medications should be prescribed only after safer options, such as regular exercise and omega-3, have been considered and/or tried.

Abstract

Although the prevalence of attention-deficit/hyperactivity disorder (ADHD) has been stable over the past 3 decades, prescriptions of sympathomimetic stimulants have steadily increased in the United States. This study consisted of a systematic review of PubMed articles screened for ADHD medications and potential cardiovascular toxicity as well as nondrug strategies for managing ADHD. The cumulative body of data showed that ADHD medications cause modest elevations in resting heart rate and blood pressure. Other adverse effects reported with ADHD stimulants included arrhythmia, nonischemic cardiomyopathy, Takotsubo cardiomyopathy, and sudden death. However, such reports did not imply causation, and there was a paucity of randomized trial evidence addressing long-term safety of ADHD medications, particularly among adults. Further studies are essential to clarify the risks and benefits of ADHD stimulant medications and to explore nonpharmacological options, including regular exercise and omega-3 fatty acids, which could be helpful for improving ADHD symptoms.

Key Words

ADHD
amphetamine salts
amphetamines
arrhythmia
atomoxetine
attention-deficit/hyperactivity disorder
cardiomyopathy
cardiotoxicity
exercise
lisdexamfetamine
methylphenidate
omega-3
sudden death

Abbreviations and Acronyms

ADHD
attention-deficit/hyperactivity disorder
ANS
autonomic nervous system
BP
blood pressure
CV
cardiovascular
CVD
cardiovascular disease
MI
myocardial infarction
RHR
resting heart rate
SNS
sympathetic nervous system
SCD
sudden cardiac death

Cited by (0)

Dr. O’Keefe has a major ownership interest in CardioTabs. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.

Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.